Share on LinkedInShare on LinkedIn

ARTICLE · 06 JULY 2017

The Promise Doctrine: Invalidated For Want Of Utility

McMillan LLP
McMillan LLP
Contributor
McMillan LLP

McMillan LLP

The firm : McMillan LLP is one of Canada’s leading national law firms with offices in Montreal,...

View firm profile
Explore more from McMillan LLP

In AstraZeneca Canada Inc. v Apotex Inc., the Supreme Court of Canada revisited the requirement of utility in the definition of "invention" in s.2 of the Patent Act.

CanadaIntellectual Property

In AstraZeneca Canada Inc. v Apotex Inc.,1 the Supreme Court of Canada revisited the requirement of utility in the definition of "invention" in s.2 of the Patent Act. The Federal Court and the Court of Appeal had held AstaZeneca's patent invalid because it failed to fully deliver on the promises made in the specification. The Supreme Court held that the application of the Promise Doctrine to an analysis of an invention's utility is ultimately the incorrect approach in law and thus AstraZeneca's patent was not invalid for want of utility.2

The Promise Doctrine

The Promise Doctrine finds its roots in the "False Promise Doctrine" from the United Kingdom in the early part of the 20th Century. At that time, patents in the UK were a grant from the Crown exercising its own discretionary power. It was presumed that the Crown granted patents on the entirety of the application being true. The courts would thus consider the patent on an invention which does not meet all its

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from